Micromedex Pediatric Reference

IBM Micromedex Pediatrics is a reliable resource for on-the-go access to evidence-based drug information to efficiently and safely manage drug therapy for pediatric patients. It allows clinicians to make accurate and more informed treatment decisions at the point of care, while minimizing errors in this vulnerable patient population. This pediatric-specific app has clinical value for doctors, nurses, and pharmacists. An internet connection is not required, allowing you to make decisions with confidence at anytime, from anywhere.

IBM Micromedex® is a trusted source for pediatric drug dosing, based on the strict editorial policies and practices that have guided Micromedex for more than 30 years. Evidence-based, fully referenced pediatric-specific drug information enables clinicians to make informed treatment decisions. The drug monographs cover information including: dose, administration, uses, contraindications/precautions, adverse effects, monitoring, pharmacology, special considerations/preparation, solution- and drug-drug compatibility/incompatibility information, and references. This mobile app also includes a comprehensive enteral formulas component providing nutritional information for approximately 100 different infant formulas and human milk fortifiers, and pediatric prescription enteral formulas.

IBM Micromedex Pediatrics drug information is intended for full-term babies 29 days of age and older (postnatal age) and preterm babies over 44 weeks postmenstrual age, up to 18 years of age.

Do you work at a facility that subscribes to IBM Micromedex Pediatrics? Check with your Chief of Pediatrics, Director of Pediatrics, Director of the PICU, Directory of Pharmacy, Chief Medical Officer, Chief Nursing Officer, Medical Librarian, or anyone else at your facility responsible for clinical reference information.

If you work at a facility that subscribes to IBM Micromedex Pediatrics Online, FREE access to these apps requires a password. To obtain the Pediatrics password contact support at:
https://www.ibm.com/support/home/pages/support-guide/?product=4592217

Existing paid customers will continue to have access to the content going forward.